These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8481908)
21. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. Dorr RT; Alberts DS J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472 [TBL] [Abstract][Full Text] [Related]
22. A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. Damen CW; Rosing H; Tibben MM; van Maanen MJ; Lagas JS; Schinkel AH; Schellens JH; Beijnen JH J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 868(1-2):102-9. PubMed ID: 18501686 [TBL] [Abstract][Full Text] [Related]
23. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Hande K; Messenger M; Wagner J; Krozely M; Kaul S Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337 [TBL] [Abstract][Full Text] [Related]
24. Increasing peak levels of vinblastine given in repeated divided doses. Van Belle SJ; de Smet MC; De Mey JE; De Neve W; Massart DL; Storme G Anticancer Res; 1992; 12(3):655-9. PubMed ID: 1622122 [TBL] [Abstract][Full Text] [Related]
25. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957 [TBL] [Abstract][Full Text] [Related]
26. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494 [TBL] [Abstract][Full Text] [Related]
27. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. van Tellingen O; Kuijpers AV; Beijnen JH; Nooijen WJ; Bult A Invest New Drugs; 1993; 11(2-3):141-50. PubMed ID: 8262726 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation. Urso R; Nencini C; Giorgi G; Fiaschi AI Eur Rev Med Pharmacol Sci; 2007; 11(6):413-7. PubMed ID: 18306910 [TBL] [Abstract][Full Text] [Related]
29. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044 [TBL] [Abstract][Full Text] [Related]
30. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Lobert S; Vulevic B; Correia JJ Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632 [TBL] [Abstract][Full Text] [Related]
31. New semisynthetic vinca alkaloids: chemical, biochemical and cellular studies. Orosz F; Comin B; Raïs B; Puigjaner J; Kovács J; Tárkányi G; Acs T; Keve T; Cascante M; Ovádi J Br J Cancer; 1999 Mar; 79(9-10):1356-65. PubMed ID: 10188876 [TBL] [Abstract][Full Text] [Related]
32. A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Loadman PM; Swaine DJ; Bibby MC; Welham KJ; Patterson LH Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):422-6. PubMed ID: 11259326 [TBL] [Abstract][Full Text] [Related]
33. Metabolism pathway of vinorelbine (Navelbine) in human: characterisation of the metabolites by HPLC-MS/MS. de Graeve J; van Heugen JC; Zorza G; Fahy J; Puozzo C J Pharm Biomed Anal; 2008 May; 47(1):47-58. PubMed ID: 18242035 [TBL] [Abstract][Full Text] [Related]
34. [New antitumor derivatives of vinblastine]. Bölcskei H; Szántay C; Mák M; Balázs M; Szántay C Acta Pharm Hung; 1998 Mar; 68(2):87-93. PubMed ID: 9592933 [TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284 [TBL] [Abstract][Full Text] [Related]
37. Optimisation of supercritical fluid extraction of indole alkaloids from Catharanthus roseus using experimental design methodology--comparison with other extraction techniques. Verma A; Hartonen K; Riekkola ML Phytochem Anal; 2008; 19(1):52-63. PubMed ID: 17654538 [TBL] [Abstract][Full Text] [Related]
38. Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection. Vendrig DE; Teeuwsen J; Holthuis JJ J Chromatogr; 1988 Jan; 424(1):83-94. PubMed ID: 3366841 [TBL] [Abstract][Full Text] [Related]
39. Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces. Zorza G; Van Heugen JC; De Graeve J; Puozzo C J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 853(1-2):294-302. PubMed ID: 17416213 [TBL] [Abstract][Full Text] [Related]
40. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]